Literature DB >> 15276702

Antipsychotic treatment of psychosis associated with multiple sclerosis.

Eugen Davids1, Ulrike Hartwig, Markus Gastpar.   

Abstract

This case report deals with the antipsychotic treatment in multiple sclerosis (MS). Psychiatric symptoms are a frequent event in patients with MS. However, there are only few systematic studies of antipsychotic treatment in MS patients. Most of the studies are related to clozapine due to the lack of neurological, particularly extrapyramidal side effects (EPS). Therefore, experiences with other atypical drugs are requested. This paper discusses the pros and cons of different atypical drugs using the example of one patient, who showed adverse effects after treatment with quetiapine and olanzapine. Risperidone was not administered with respect to possible EPS. However, ziprasidone was tolerated well and appeared to be effective.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276702     DOI: 10.1016/j.pnpbp.2004.05.010

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  9 in total

1.  Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment.

Authors:  Ida S Haussleiter; Martin Brüne; Georg Juckel
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

2.  Manifestation of multiple sclerosis with paranoid-hallucinatory psychosis.

Authors:  Jens Reimer; Volkmar Aderhold; Martin Lambert; Christian Haasen
Journal:  J Neurol       Date:  2006-02-03       Impact factor: 4.849

3.  Improvement of neuropsychiatric symptoms in multiple sclerosis subsequent to high-dose corticosteroid treatment.

Authors:  Jan Thöne; Elke Kessler
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 4.  Dopamine, T cells and multiple sclerosis (MS).

Authors:  Mia Levite; Franca Marino; Marco Cosentino
Journal:  J Neural Transm (Vienna)       Date:  2017-03-10       Impact factor: 3.575

5.  Temporal lobe lesions and psychosis in multiple sclerosis.

Authors:  R Yadav; A S Zigmond
Journal:  BMJ Case Rep       Date:  2010-10-12

Review 6.  Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?

Authors:  Marco Cosentino; Franca Marino
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-17       Impact factor: 4.147

7.  Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase I, randomised, blinded, placebo-controlled trial.

Authors:  Anne C La Flamme; David Abernethy; Dalice Sim; Liz Goode; Michelle Lockhart; David Bourke; Imogen Milner; Toni-Marie Garrill; Purwa Joshi; Eloise Watson; Duncan Smyth; Sean Lance; Bronwen Connor
Journal:  BMJ Neurol Open       Date:  2020-07-09

8.  Multiple sclerosis presents with psychotic symptoms and coexists with hypertrophic cardiomyopathy.

Authors:  Muhammed Emin Ozcan; Bahri Ince; Hasan Hüseyin Karadeli; Talip Asil
Journal:  Case Rep Neurol Med       Date:  2014-08-13

9.  [Acute psychotic episode as a primary clinical manifestation of multiple sclerosis-a case report].

Authors:  Sharmili Edwin Thanarajah; Hannah Wendy; Andreas Reif; Christine Reif-Leonhard
Journal:  Nervenarzt       Date:  2021-03-24       Impact factor: 1.214

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.